Business Context and Reporting Period
Company: Kewaunee Scientific Corporation (KEQU)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended July 31, 2026
Business Overview: The Company operates in two segments: Lab Products Group (LPG), which designs and manufactures scientific furniture and equipment, and International, which provides laboratory facility design and construction services. The Company is a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 FY2027 (Ended July 31, 2026) | Q1 FY2026 (Ended July 31, 2025) |
|---|---|---|
| Net Sales | $66.32 million | $71.10 million |
| Gross Profit | $19.64 million | $20.93 million |
| Gross Margin | 29.6% | 29.4% |
| Operating Profit | $3.16 million | $4.81 million |
| Net Earnings (Attributable to Kewaunee) | $1.71 million | $3.09 million |
| Diluted EPS | $0.58 | $1.04 |
| Operating Cash Flow | $1.98 million | $5.79 million |
| Free Cash Flow | $1.20 million | $5.02 million |
| Total Debt (Long-term + Current) | $47.26 million | Not directly comparable due to refinancing |
| Working Capital | $56.72 million | N/A |
| Order Backlog | $169.0 million | $205.0 million |
Note: Total Debt includes Term Loans ($18.83M), Sale-Leaseback Financing Liability ($26.42M), and short-term borrowings ($0.63M).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.7% year-over-year. The LPG segment declined 6.4% due to lower demand in the domestic life sciences market. The International segment declined 7.8% due to softer conditions in India, partially offset by growth in the Asia-Pacific region.
- Profitability Compression: Operating profit decreased 34.3% to $3.16 million. While gross margin improved slightly to 29.6%, operating expenses increased as a percentage of sales (24.9% vs. 22.7% prior year), driven largely by a significant increase in stock-based compensation expense ($1.90 million vs. $0.52 million).
- Interest Expense Reduction: Interest expense dropped 40.8% to $0.63 million, primarily due to the repayment of subordinated seller notes in December 2025 and lower borrowing levels.
- Tax Rate Increase: The effective tax rate rose to 28.0% from 19.4%, reflecting the mix of domestic and foreign earnings and expenses related to the indefinite reinvestment assertion for Indian subsidiaries.
- Cash Flow Weakness: Operating cash flow decreased significantly to $1.98 million, impacted by a $3.0 million decrease in accounts payable and other accrued expenses.
Outlook, Risks, and Management Commentary
- Market Conditions: Management cites broad geopolitical and economic uncertainty impacting project award and release timelines. However, quoting activity remains strong, and customer engagement is healthy.
- Strategy: The Company is focusing on operational improvements, commercial capability enhancements, and disciplined execution to convert quoting activity into project awards.
- Liquidity: The Company maintains a $20.0 million revolving credit facility with PNC, with no advances outstanding as of July 31, 2026. Management believes current sources of liquidity are sufficient for ongoing requirements.
- Capital Allocation: The Company repurchased 14,290 shares of common stock for approximately $0.53 million. 86,313 shares remain available under the repurchase program.
- Risks: Key risks include dependence on laboratory construction projects, fluctuations in raw material costs (steel, wood, epoxy resin), foreign currency fluctuations, and supply chain disruptions.
Investor Verification Checklist
- Backlog Trend: Verify the sustainability of the order backlog, which has declined from $205.0 million (July 2025) to $169.0 million (July 2026).
- Stock-Based Compensation: Review the impact of the $1.90 million stock-based compensation expense on future quarters, as this was a significant driver of operating expense growth.
- International Exposure: Assess the specific risks and recovery potential in the Indian market, which contributed to the International segment's decline.
- Debt Covenants: Confirm continued compliance with the Amended Loan Agreement covenants (Senior Debt/EBITDA ≤ 2.50x; Fixed Charge Coverage ≥ 1.20x).
- Deferred Revenue: Monitor the $5.19 million deferred revenue balance, approximately 92% of which is expected to be recognized in the succeeding 12 months.